Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics
This article was originally published in PharmAsia News
Executive Summary
In a surprise move spurred by a desire to own a greater share of the promising angina drug Ranexa, Astellas announced Jan. 27 its hostile offer for partner CV Therapeutics in a cash deal worth roughly $1 billion